<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tumors</journal-id><journal-title-group><journal-title xml:lang="ru">Malignant tumours</journal-title><trans-title-group xml:lang="en"><trans-title>Malignant tumours</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2224-5057</issn><issn pub-type="epub">2587-6813</issn><publisher><publisher-name>Rosoncoweb</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18027/2224-5057-2019-9-2-27-34</article-id><article-id custom-type="elpub" pub-id-type="custom">tumors-636</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group></article-categories><title-group><article-title>Центральная шейная лимфодиссекция при хирургическом лечении папиллярного рака щитовидной железы</article-title><trans-title-group xml:lang="en"><trans-title>Central neck lymph node dissection for papillary thyroid cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кропотов</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kropotov</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил А. Кропотов - доктор медицинских наук, ведущий научный сотрудник отделения опухолей головы и шеи</p></bio><bio xml:lang="en"/><email xlink:type="simple">drkropotov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гривачев</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Grivachev</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евгений А. Гривачев - студент</p></bio><bio xml:lang="en"><p>Evgeniy A. Grivachev - student</p></bio><email xlink:type="simple">djek-aleksandrov@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковлева</surname><given-names>Л. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakovleva</surname><given-names>L. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лилия П. Яковлева - кандидат медицинских наук, заведующая отделением опухолей головы и шеи</p></bio><bio xml:lang="en"><p>Liliya P. Yakovleva - MD, PhD, Head of the Department of Head and Neck Tumors</p></bio><email xlink:type="simple">l.yakovleva@mknc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ходос</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khodos</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Артем В. Ходос - врач отделения опухолей головы и шеи</p></bio><bio xml:lang="en"><p>Artem V. Khodos - physician of the Department of Head and Neck Tumors</p></bio><email xlink:type="simple">khodos.av@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тигров</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Tigrov</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил С. Тигров - аспирант отделения опухолей головы и шеи</p></bio><bio xml:lang="en"/><email xlink:type="simple">tigrov.92@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ «Московский клинический научный центр им. А.С. Логинова» ДЗМ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.S. Loginov Moscow Clinical Scientific Center of the Department of Health of the City of Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый МГМУ им. И.М. Сеченова МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>27</day><month>06</month><year>2019</year></pub-date><volume>9</volume><issue>2</issue><fpage>27</fpage><lpage>34</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кропотов М.А., Гривачев Е.А., Яковлева Л.П., Ходос А.В., Тигров М.С., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Кропотов М.А., Гривачев Е.А., Яковлева Л.П., Ходос А.В., Тигров М.С.</copyright-holder><copyright-holder xml:lang="en">Kropotov M.A., Grivachev E.A., Yakovleva L.P., Khodos A.V., Tigrov M.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.malignanttumors.org/jour/article/view/636">https://www.malignanttumors.org/jour/article/view/636</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Клиническое течение папиллярного рака щитовидной железы характеризуется частым метаста-зированием в регионарные лимфатические узлы, к которым относятся лимфоузлы центральной клетчатки шеи и глубокие яремные лимфоузлы. Выявление метастатического поражения паратрахеальных лимфоузлов при высокодифференцированном раке щитовидной железы с первичной опухолью, соответствующей T1-2, сопровождается высокой частотой ложноотрицательных результатов. Выполнение повторных оперативных вмешательств на этой зоне является технически сложным и сопровождается определенным числом осложнений. Таким образом, профилактическое удаление клетчатки центральной зоны предотвращает локальный рецидив и дальнейшее метастатическое распространение в регионарные лимфатические узлы, а также помогает правильно стадировать процесс и, следовательно, сформировать тактику дальнейшего лечения пациента.</p></sec><sec><title>Цель работы</title><p>Цель работы. Определение оптимального объема хирургического вмешательства при папиллярном раке щитовидной железы.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включено 60 больных, прооперированных по поводу папиллярного рака щитовидной железы. Набор клинического материала осуществлялся на базе ГБУЗ МКНЦ им. А.С. Логинова ДЗМ с 2015 по 2017 гг.</p></sec><sec><title>Результаты</title><p>Результаты. Регионарные метастазы в лимфатических узлах центральной клетчатки шеи после выполнения профилактической центральной шейной лимфодиссекции выявлены в 41,5% случаев. При динамическом наблюдении в сроки до 18 месяцев ни у одного пациента не отмечалось рецидива в виде регионарных и отдаленных метастазов.</p></sec><sec><title>Выводы</title><p>Выводы. Клиническое течение папиллярного рака щитовидной железы характеризуется высоким индексом регионарного метастазирования в лимфатические узлы центральной клетчатки шеи, что диктует необходимость выполнения вместе с тиреоидэктомией центральной ипсилатеральной лимфодиссекции, не увеличивающей частоту послеоперационных осложнений.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. Papillary thyroid cancer is often associated with regional metastases to lymph nodes including those of the central adipose tissue of the neck and the deep jugular lymph nodes. Assessment of metastatic involvement of the paratracheal lymph nodes in patients with well-differentiated thyroid cancer T1 and T2 is known to often produce false negative results. Surgical procedures in this region are technically challenging and associated with a certain risk of complications. Therefore, prophylactic removal of the central adipose tissue prevents local cancer recurrence and further metastatic involvement of the regional lymph nodes; moreover, it contributes to proper disease staging and planning of further patient management.</p></sec><sec><title>Study goal</title><p>Study goal. Was to determine the optimal extent of surgery for papillary thyroid cancer.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Sixty patients who underwent surgical procedures for papillary thyroid cancer were enrolled in the study. The study was carried out at SBHI Moscow Clinical Scientific Center named after A.S. Loginov of Moscow City Department of Healthcare from 2015 to 2017.</p></sec><sec><title>Results</title><p>Results. Regional metastases to the lymph nodes of the central adipose tissue of the neck removed during prophylactic central cervical lymph node dissection were revealed in 41.5% of cases. None of the patients demonstrated regional or distant metastases within 18 months of follow-up.</p></sec><sec><title>Conclusions</title><p>Conclusions. Papillary thyroid cancer is associated with high incidence of regional metastases to the lymph nodes of the central adipose tissue of the neck, which necessitates central ipsilateral lymph node dissection simultaneously with thyroidectomy, which does not increase the postoperative complication rate.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>щитовидная железа</kwd><kwd>тиреоидэктомия</kwd><kwd>лимфодиссекция</kwd><kwd>папиллярный рак</kwd><kwd>высокодифференцированный рак щитовидной железы</kwd><kwd>гипопаратиреоз</kwd><kwd>возвратный нерв</kwd><kwd>центральная клетчатка шеи</kwd></kwd-group><kwd-group xml:lang="en"><kwd>thyroid</kwd><kwd>thyroidectomy</kwd><kwd>lymph node dissection</kwd><kwd>papillary cancer</kwd><kwd>well-differentiated thyroid cancer</kwd><kwd>hypoparathyroidism</kwd><kwd>recurrent laryngeal nerve</kwd><kwd>central adipose tissue of the neck</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin (2011) 61 (2):61-90. doi:10.3322/caac.20</mixed-citation><mixed-citation xml:lang="en">Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin (2011) 61 (2):61-90. doi:10.3322/caac.20</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Hundahl SA, Fleming ID, Fremgen AM, Menck HR, et al. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985-1995. Cancer (1998) 839 (12):2638-48. doi:10.1002/(SICI)1097-0142(19981215)83:12&lt;2638::AID-CNCR31&gt;3.0.CO;2-1</mixed-citation><mixed-citation xml:lang="en">Hundahl SA, Fleming ID, Fremgen AM, Menck HR, et al. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985-1995. Cancer (1998) 839 (12):2638-48. doi:10.1002/(SICI)1097-0142(19981215)83:12&lt;2638::AID-CNCR31&gt;3.0.CO;2-1</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, et al. Immediate cuases of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab (1999) 84 (11):4043-94. doi:10.1210/jcem.84.11.6115</mixed-citation><mixed-citation xml:lang="en">Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, et al. Immediate cuases of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab (1999) 84 (11):4043-94. doi:10.1210/jcem.84.11.6115</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Grebe S.K., Hay I.D. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg.Oncol.Clin.North Am., 1996, 5, 43-46.</mixed-citation><mixed-citation xml:lang="en">Grebe S.K., Hay I.D. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg.Oncol.Clin.North Am., 1996, 5, 43-46.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kouvaraki M.A., Shapiro S.E., Fornage B.D., et al. Role of preoperative ulthrasonography in the surgical management of patients with thyroid cancer. Surgery, 2003, 134, 946-954.</mixed-citation><mixed-citation xml:lang="en">Kouvaraki M.A., Shapiro S.E., Fornage B.D., et al. Role of preoperative ulthrasonography in the surgical management of patients with thyroid cancer. Surgery, 2003, 134, 946-954.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Л.П. Яковлева «Диагностика местнораспространенного рака щитовидной железы» Автореферат канд. Дисс. 2005.</mixed-citation><mixed-citation xml:lang="en">Л.П. Яковлева «Диагностика местнораспространенного рака щитовидной железы» Автореферат канд. Дисс. 2005.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bhattacharyya N. Surgical treatment of cervical nodal metastases in patients with papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 2003, 129 (10), 1101-1104.</mixed-citation><mixed-citation xml:lang="en">Bhattacharyya N. Surgical treatment of cervical nodal metastases in patients with papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 2003, 129 (10), 1101-1104.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Scheumann G.F., Gimm O., Wegener G. et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J. Surg. 1994;18 (4):559-567.</mixed-citation><mixed-citation xml:lang="en">Scheumann G.F., Gimm O., Wegener G. et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J. Surg. 1994;18 (4):559-567.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med (1994) 97 (5):418-28. doi:10.1016/0002-9343(94)90321-2</mixed-citation><mixed-citation xml:lang="en">Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med (1994) 97 (5):418-28. doi:10.1016/0002-9343(94)90321-2</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg (2005) 71 (9):731-4.</mixed-citation><mixed-citation xml:lang="en">Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg (2005) 71 (9):731-4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery (2008) 144 (6):1070-7. doi:10.1016/j.surg.2008.08.034</mixed-citation><mixed-citation xml:lang="en">Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery (2008) 144 (6):1070-7. doi:10.1016/j.surg.2008.08.034</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzaferri EL. A vision for the surgical management of papillary thyroid carcinoma: extensive lymph node compartmental dissections and selective use of radioiodine. J Clin Endocrinol Metab (2009) 94 (4):1086-8. doi:10.1210/jc.2009-0298</mixed-citation><mixed-citation xml:lang="en">Mazzaferri EL. A vision for the surgical management of papillary thyroid carcinoma: extensive lymph node compartmental dissections and selective use of radioiodine. J Clin Endocrinol Metab (2009) 94 (4):1086-8. doi:10.1210/jc.2009-0298</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zaydfudim V., Feurer I.D., Griffin M.R. et al. The impact of lymph node involvement on survival in patient with papillary and follicular thyroid carcinoma. Surgery, 2008, 144, 1070-1077.</mixed-citation><mixed-citation xml:lang="en">Zaydfudim V., Feurer I.D., Griffin M.R. et al. The impact of lymph node involvement on survival in patient with papillary and follicular thyroid carcinoma. Surgery, 2008, 144, 1070-1077.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Popadich A, Levin O, Lee JC, Smooke-Praw S, Ro K, Fazel M, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery (2011) 150:1048-57. doi:10.1016/j.surg.2011.09.003</mixed-citation><mixed-citation xml:lang="en">Popadich A, Levin O, Lee JC, Smooke-Praw S, Ro K, Fazel M, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery (2011) 150:1048-57. doi:10.1016/j.surg.2011.09.003</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">So YK, Seo MY, Son YI. Prophylactic central lymph node dissection for clinically node-negative papillary thyroid microcarcinoma: influence on serum thyroglobulin level, recurrence rate, and postoperative complications. Surgery (2012) 151:192-8. doi:10.1016/j.surg.2011.02.004</mixed-citation><mixed-citation xml:lang="en">So YK, Seo MY, Son YI. Prophylactic central lymph node dissection for clinically node-negative papillary thyroid microcarcinoma: influence on serum thyroglobulin level, recurrence rate, and postoperative complications. Surgery (2012) 151:192-8. doi:10.1016/j.surg.2011.02.004</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery (2006) 140 (6):1000-5. doi:10.1016/j.surg.2006.08.001</mixed-citation><mixed-citation xml:lang="en">Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery (2006) 140 (6):1000-5. doi:10.1016/j.surg.2006.08.001</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Shan CX, Zhang W, Jiang DZ, Zheng XM, Liu S, Qiu M. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. Laryngoscope (2012) 122 (4):797-804. doi:10.1002/lary.22162</mixed-citation><mixed-citation xml:lang="en">Shan CX, Zhang W, Jiang DZ, Zheng XM, Liu S, Qiu M. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. Laryngoscope (2012) 122 (4):797-804. doi:10.1002/lary.22162</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Roh JL, Kim JM, Park CL. Central compartment reoperation for recurrent / persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia. Ann Surg Oncol (2011) 18 (5):1312-8. doi:10.1245/s10434-010-1470-9.</mixed-citation><mixed-citation xml:lang="en">Roh JL, Kim JM, Park CL. Central compartment reoperation for recurrent / persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia. Ann Surg Oncol (2011) 18 (5):1312-8. doi:10.1245/s10434-010-1470-9.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Coatesworth AP, MacLennan K. Cervical metastasis in papillary carcinoma of the thyroid: a histopathological study. Int J Clin Pract (2002) 56:241-2.</mixed-citation><mixed-citation xml:lang="en">Coatesworth AP, MacLennan K. Cervical metastasis in papillary carcinoma of the thyroid: a histopathological study. Int J Clin Pract (2002) 56:241-2.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ducci M, Appetecchia M, Marzetti M. Neck dissection for surgical treatment of lymph node metastasis in papillary thyroid carcinoma. J Exp Clin Cancer Res (1997) 16:333-5.</mixed-citation><mixed-citation xml:lang="en">Ducci M, Appetecchia M, Marzetti M. Neck dissection for surgical treatment of lymph node metastasis in papillary thyroid carcinoma. J Exp Clin Cancer Res (1997) 16:333-5.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lee YS, Shin SC, Lim YS, Lee JC, Wang SG, Son SM, et al. Tumor location-dependent skip lateral cervical lymph node metastasis in papillary thyroid cancer. Head Neck (2014) 36 (6):887-91. doi:10.1002/hed.23391</mixed-citation><mixed-citation xml:lang="en">Lee YS, Shin SC, Lim YS, Lee JC, Wang SG, Son SM, et al. Tumor location-dependent skip lateral cervical lymph node metastasis in papillary thyroid cancer. Head Neck (2014) 36 (6):887-91. doi:10.1002/hed.23391</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Chisholm EJ, Kulinskaya E, Tollery NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope (2009) 119 (6):1135-9. doi:10.1002/lary.20236</mixed-citation><mixed-citation xml:lang="en">Chisholm EJ, Kulinskaya E, Tollery NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope (2009) 119 (6):1135-9. doi:10.1002/lary.20236</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer: revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 19 (11):1167—214. doi:10.1089/thy.2009.0110</mixed-citation><mixed-citation xml:lang="en">Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer: revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 19 (11):1167—214. doi:10.1089/thy.2009.0110</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid (2016) 261:1-133. doi:10.1089/thy.2015.0020</mixed-citation><mixed-citation xml:lang="en">Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid (2016) 261:1-133. doi:10.1089/thy.2015.0020</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res (2011) 17 (24):7511-7. doi:10.1158/1078-0432.CCR-11-1155</mixed-citation><mixed-citation xml:lang="en">Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res (2011) 17 (24):7511-7. doi:10.1158/1078-0432.CCR-11-1155</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, et al. BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg (2012) 36:310-7. doi:10.1007/s00268-011-1383-1.</mixed-citation><mixed-citation xml:lang="en">Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, et al. BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg (2012) 36:310-7. doi:10.1007/s00268-011-1383-1.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/ persistent papillary thyroid cancer: efficacy, safety, and association of the BRAF mutation. Laryngoscope (2012) 122:1634-40. doi:10.1002/lary.23371</mixed-citation><mixed-citation xml:lang="en">Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/ persistent papillary thyroid cancer: efficacy, safety, and association of the BRAF mutation. Laryngoscope (2012) 122:1634-40. doi:10.1002/lary.23371</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 89 (6):2867-72. doi:10.1210/jc.2003-032050</mixed-citation><mixed-citation xml:lang="en">Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 89 (6):2867-72. doi:10.1210/jc.2003-032050</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol (2013) 20 (1):47-52.doi:10.1245/s10434-012-2611-0</mixed-citation><mixed-citation xml:lang="en">Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol (2013) 20 (1):47-52.doi:10.1245/s10434-012-2611-0</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, et al. Association of BRAF V600E mutation and microRNA expression with central lymph node metastases in papillary thyroid cancer: a prospective study from four endocrine surgery centers. Thyroid (2016) 26 (4):532-42. doi:10.1089/thy.2015.0378</mixed-citation><mixed-citation xml:lang="en">Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, et al. Association of BRAF V600E mutation and microRNA expression with central lymph node metastases in papillary thyroid cancer: a prospective study from four endocrine surgery centers. Thyroid (2016) 26 (4):532-42. doi:10.1089/thy.2015.0378</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, et al. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery (2015) 158 (6):1500—11. doi:10.1016/j.surg.2015.05.016</mixed-citation><mixed-citation xml:lang="en">Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, et al. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery (2015) 158 (6):1500—11. doi:10.1016/j.surg.2015.05.016</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol (2014) 32 (25):2718-26. doi:10.1200/JC0.2014.55.5094</mixed-citation><mixed-citation xml:lang="en">Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol (2014) 32 (25):2718-26. doi:10.1200/JC0.2014.55.5094</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ywata de Carvalho, A., Chulam, T.C., and Kowalski, L.P. Long-term results of observation vs prophylactic selective level VI neck dissection for papillary thyroid carcinoma at a cancer center. JAMA Otolaryngol Head Neck Surg. — 2015.-pp 141: 599-606</mixed-citation><mixed-citation xml:lang="en">Ywata de Carvalho, A., Chulam, T.C., and Kowalski, L.P. Long-term results of observation vs prophylactic selective level VI neck dissection for papillary thyroid carcinoma at a cancer center. JAMA Otolaryngol Head Neck Surg. — 2015.-pp 141: 599-606</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ma, B., Wang, Y., Yang, S., and Ji, Q. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma: a systematic review and meta-analysis Int J Surg.2016.-pp 289: 153-161</mixed-citation><mixed-citation xml:lang="en">Ma, B., Wang, Y., Yang, S., and Ji, Q. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma: a systematic review and meta-analysis Int J Surg.2016.-pp 289: 153-161</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
